I think, from a calendar timing perspective, the next quarter will be the biggest miss in many years. Reason: Lower research grants will impact the 1st semester (starting in September) of the research year the greatest.
It is becoming increasingly clear Congress primary focus will be spending reduction, most likely via another sequester. Since spending already is down over the past several months, another reduction via across the board reductions just makes this much worse.... right in the period when WTR usually has the greatest sales.
See news for full story:
"Beaudouin Mark T who is VP and General Counsel at Waters Corp. (NYSE:WAT), sold 97,303 shares at $102.00 per share for a total value of $9,925,306."
"Rae Elizabeth B who is Corporate VP of HR at Waters Corp. (NYSE:WAT), sold 40,000 shares at $102.00 per share for a total value of $4,080,000."
Their firewall and security protection software is excellent with particularly superior focus on privacy and elimination of trace data.
FB should be fine so long as they grow revenue at a 30 percent clip, taking ad money from Google.
The net income numbers are so small it is almost irrelevant. Perhaps investors will view FB as a new AMZN where revenue is the only number that matters and profitability is nonsense.
A bank should have a Tier-1 capital ratio above 10.00, a price to book value under 1.50 and positive retained earnings to have any value. FMAR doesn't meet any of that criteria. In fact it has a negative book value and huge negative retained earnings. It remains on FDIC negative watch list does it not?
Does it mean AxoGen owes somebody some money ahead of shareholders?
It is going to get worse as more and more tea party folks get elected.
The next round of talks in Congress will determine the future of WAT from USA revenue potential.
I guess outside USA sales could rise as other countries begin to ramp up basic research as USA winds down.
Simple. This is private industry in the business of making a profit. That means they sell the higher margin products and drop the unprofitable ones. This niche in particular has low margins as it is and thus no space for negative margins.
ESRX is doing what a private company should do.... decide which medications to distribute.
That is the situation right now. Most R&D at universities is government funded. Grant folks at NIH (for example) are deemed "non essential". Of course low level lab technicians are "essential" to care for research projects already ongoing to monitor those virus, bacteria and lab animals (etc),
Pray that Jana Partners is getting out. We need agriculture buyers on the other side of the trade (folks who know agriculture)
There is only one offer and it is $35 per share. Shareholders voted on that offer and said yes.
End of story.
All this garbage coming out in recent pundit press releases is just that... garbage generated by sewer rats.
Does Cooper management have some sort of back office agreement with Apollo?
As soon as shareholders voted, management started agreeing on a lower price?
Vote them all out!!!!!!!!!!!!!!
GT current ratio is not even close to CTB: GT Current Ratio (mrq): 1.73 which indicates CTB debt is minor compared to one of its peers.